We've shut down the self-health mailing list. We're also no longer accepting angel checks :)

But I also have good news: you're on this new list because I've deeply appreciated your support and engagement through our journey.

Semaglutide (Ozempic, Wegovy) is a remarkably effective weight loss drug.

Since approval in 2021, this and other drugs in the same category of GLP-1 agonists such as tirzepatide (Zepbound, Mounjaro) and orforglipron (Foundayo) have become so popular that over 1 in every 8 Americans have tried one.

Because the GLP-1 drugs work. Side effects are mild for most people, and the clinical safety evidence is overwhelming.

Many think these drugs cost over $1,000 a month -- retail sticker. Popular manufacturer discounts bring that price to just under $500. But the industry secret? 503A compounding pharmacies today can bring the cost of official medications down to less than $100 for a full month supply.

The top GLP-1 companies today make their money on drug markups. We make our money from clinical care with medications at-cost. Our incentives are aligned only with patient health, not selling or withholding drugs.

Last week I watched a 21-year-old casually talking to some high schoolers about growth hormone injections over tennis. From hormone replacement therapy, to weight loss, dermatology, pain management, and sports performance, personalized medications are going increasingly mainstream. The resulting demand compounding pharmacies see is already huge today.

But the market is opaque. There are over 30,000 503A compounding pharmacies with no standard for navigating price, quality, and trust. Buyers navigate on word-of-mouth and Reddit reviews.

There will be only one standard for how Americans access compounded medications. The first personalized medication marketplace will set the bar for transparency that every patient will expect and every 503A pharmacy will need to adhere to. We're racing to build this now, starting with GLP-1s.

How you can help

Who else would benefit from more transparency in compounded medication markets like GLP-1 weight loss drugs?

Let us know if there are investors, operators, or other people we should reach out to.

Confidential -- friends, investors, and insiders only!